SE444887B - Tvaskiktstablett innehallande pivaloyloximetyl-6-/(hexahydro-1h-azepin-1-yl)-metylenamino/-penicillanat och pivaloyloximetyl-6-(d-alfa-aminofenylacetamido)-penicillanat - Google Patents
Tvaskiktstablett innehallande pivaloyloximetyl-6-/(hexahydro-1h-azepin-1-yl)-metylenamino/-penicillanat och pivaloyloximetyl-6-(d-alfa-aminofenylacetamido)-penicillanatInfo
- Publication number
- SE444887B SE444887B SE8006592A SE8006592A SE444887B SE 444887 B SE444887 B SE 444887B SE 8006592 A SE8006592 A SE 8006592A SE 8006592 A SE8006592 A SE 8006592A SE 444887 B SE444887 B SE 444887B
- Authority
- SE
- Sweden
- Prior art keywords
- tablet
- layer
- component
- pivaloyloximethyl
- penicillanate
- Prior art date
Links
- -1 (HEXAHYDRO-1H-AZEPIN-1-YL) -METHYLENAMINO Chemical class 0.000 title description 2
- 239000007884 disintegrant Substances 0.000 claims description 9
- 101000623895 Bos taurus Mucin-15 Proteins 0.000 claims description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 6
- 239000007888 film coating Substances 0.000 claims description 5
- 238000009501 film coating Methods 0.000 claims description 5
- 239000012458 free base Substances 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 231100000252 nontoxic Toxicity 0.000 claims description 2
- 230000003000 nontoxic effect Effects 0.000 claims description 2
- 239000011149 active material Substances 0.000 claims 2
- 239000003826 tablet Substances 0.000 description 35
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 10
- 239000008187 granular material Substances 0.000 description 10
- 229960003342 pivampicillin Drugs 0.000 description 8
- ZEMIJUDPLILVNQ-ZXFNITATSA-N pivampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)[C@H](C(S3)(C)C)C(=O)OCOC(=O)C(C)(C)C)=CC=CC=C1 ZEMIJUDPLILVNQ-ZXFNITATSA-N 0.000 description 8
- UHPXMYLONAGUPC-WKLLBTDKSA-N pivmecillinam hydrochloride Chemical compound [H+].[Cl-].N([C@H]1[C@@H]2N(C1=O)[C@H](C(S2)(C)C)C(=O)OCOC(=O)C(C)(C)C)=CN1CCCCCC1 UHPXMYLONAGUPC-WKLLBTDKSA-N 0.000 description 7
- 229940037380 pivmecillinam hydrochloride Drugs 0.000 description 7
- 239000004480 active ingredient Substances 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 229920002472 Starch Polymers 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 239000008107 starch Substances 0.000 description 5
- 235000019698 starch Nutrition 0.000 description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 4
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 4
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 4
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 4
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 4
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 4
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 229920000609 methyl cellulose Polymers 0.000 description 3
- 239000001923 methylcellulose Substances 0.000 description 3
- 235000010981 methylcellulose Nutrition 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- NPGNOVNWUSPMDP-UTEPHESZSA-N chembl1650818 Chemical compound N(/[C@H]1[C@@H]2N(C1=O)[C@H](C(S2)(C)C)C(=O)OCOC(=O)C(C)(C)C)=C\N1CCCCCC1 NPGNOVNWUSPMDP-UTEPHESZSA-N 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 229960004212 pivmecillinam Drugs 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 238000007098 aminolysis reaction Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000004880 explosion Methods 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000003979 granulating agent Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
Landscapes
- Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB7932902 | 1979-09-21 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| SE8006592L SE8006592L (sv) | 1981-03-22 |
| SE444887B true SE444887B (sv) | 1986-05-20 |
Family
ID=10508005
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SE8006592A SE444887B (sv) | 1979-09-21 | 1980-09-19 | Tvaskiktstablett innehallande pivaloyloximetyl-6-/(hexahydro-1h-azepin-1-yl)-metylenamino/-penicillanat och pivaloyloximetyl-6-(d-alfa-aminofenylacetamido)-penicillanat |
Country Status (8)
| Country | Link |
|---|---|
| AT (1) | AT371711B (enExample) |
| AU (1) | AU532764B2 (enExample) |
| DE (1) | DE3035509A1 (enExample) |
| FR (1) | FR2465479A1 (enExample) |
| IT (1) | IT1209809B (enExample) |
| NL (1) | NL8005252A (enExample) |
| NZ (1) | NZ194785A (enExample) |
| SE (1) | SE444887B (enExample) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1405866A (en) * | 1919-12-12 | 1922-02-07 | Frank X Ratkovic | Planting machine |
| GB1405886A (en) * | 1971-11-01 | 1975-09-10 | Astra Laekemedel Ab | Synergistic compositions comprising penicillin and cephalosporin antibiotics |
| GB1478598A (en) * | 1974-05-17 | 1977-07-06 | Leo Pharm Prod Ltd | Antibiotic mixture |
-
1980
- 1980-08-27 NZ NZ194785A patent/NZ194785A/xx unknown
- 1980-09-15 AT AT0461480A patent/AT371711B/de not_active IP Right Cessation
- 1980-09-19 FR FR8020247A patent/FR2465479A1/fr active Granted
- 1980-09-19 SE SE8006592A patent/SE444887B/sv not_active IP Right Cessation
- 1980-09-19 AU AU62564/80A patent/AU532764B2/en not_active Ceased
- 1980-09-19 NL NL8005252A patent/NL8005252A/nl not_active Application Discontinuation
- 1980-09-19 IT IT8068456A patent/IT1209809B/it active
- 1980-09-19 DE DE19803035509 patent/DE3035509A1/de not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| DE3035509A1 (de) | 1981-04-09 |
| AT371711B (de) | 1983-07-25 |
| IT8068456A0 (it) | 1980-09-19 |
| IT1209809B (it) | 1989-08-30 |
| AU532764B2 (en) | 1983-10-13 |
| NL8005252A (nl) | 1981-03-24 |
| FR2465479B1 (enExample) | 1984-11-02 |
| SE8006592L (sv) | 1981-03-22 |
| AU6256480A (en) | 1981-04-09 |
| FR2465479A1 (fr) | 1981-03-27 |
| NZ194785A (en) | 1983-05-31 |
| ATA461480A (de) | 1982-12-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0665744B1 (en) | Stable extended release oral dosage composition | |
| EP1096937B1 (en) | Sustained release ranolazine formulations | |
| US11660308B2 (en) | Pharmaceutical composition comprising dapagliflozin | |
| US6210716B1 (en) | Controlled release bupropion formulation | |
| US5830503A (en) | Enteric coated diltiazem once-a-day formulation | |
| PH26146A (en) | Sustained release etodolac | |
| US5968553A (en) | Pharmaceutical composition containing bupropion hydrochloride and an inorganic acid stabilizer | |
| NZ238131A (en) | Chewable medicament tablets formed from compressed coated granules; coating is a polymer blend masking taste and providing sustained release | |
| WO2002003914A2 (en) | Improved thyroid hormone formulations | |
| SK282506B6 (sk) | Tableta obsahujúca paracetamol a domperidon | |
| US4520009A (en) | Sustained released aspirin formulation | |
| KR20120012823A (ko) | 신경보호 및 퇴행성 신경 질환 치료용 클라블라네이트 제제 | |
| CN107205969A (zh) | 糖尿病治疗用药物组合物 | |
| SI8710406B (sl) | Tablete s podaljšanim delovanjem na osnovi hidroksipropilmetilceluloze z veliko molsko maso in postopek za njihovo pripravo | |
| US5853756A (en) | Controlled release formulations of Ranitidine | |
| EP1178780A1 (en) | Multiparticulate controlled release selective serotonin reuptake inhibitor formulations | |
| GB2058565A (en) | Layer tablets | |
| SE444887B (sv) | Tvaskiktstablett innehallande pivaloyloximetyl-6-/(hexahydro-1h-azepin-1-yl)-metylenamino/-penicillanat och pivaloyloximetyl-6-(d-alfa-aminofenylacetamido)-penicillanat | |
| US20020172727A1 (en) | Multiparticulate formulations of lithium salts for oral administration suitable for once-a-day administration | |
| HU183053B (en) | Process for heatstabilizing and form-stabilizing soft gelatine capsules containing active agents inside the envelope utilizable perlingual and buccal application | |
| CA1326632C (en) | Long-active drug formulations comprising galanthamine for treatment of alzheimer's disease | |
| EP0761209A2 (en) | Controlled release formulations of ranitidine | |
| US3485914A (en) | Process for the production of a pharmaceutical antibiotic preparation having delayed therapeutic action and the composition prepared according to such process | |
| KR101320016B1 (ko) | 안정화된 코엔자임ｑ10, 종합 비타민 및 미네랄 성분을함유하는 복합제제 | |
| US9694007B2 (en) | Oral complex composition comprising pseudoephedrine and levocetirizine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| NUG | Patent has lapsed |
Ref document number: 8006592-3 Effective date: 19930406 Format of ref document f/p: F |